Etanercept biosimilar is under clinical development by Mabxience Holding and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Etanercept biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Etanercept biosimilar overview
Etanercept biosimilar is under development for the treatment of autoimmune disorders. The drug candidate was administered subcutaneously. It was a dimeric fusion protein targeting lymphotoxin alpha (TNF Beta) and tumor necrosis factor (TNF alpha) linked to the Fc portion of human IgG1.
Mabxience Holding overview
Mabxience Holding (mAbxience), a subsidiary of Fresenius Kabi AG, is a biotechnology company specializing in the research, development and manufacturing of biosimilar monoclonal antibodies. The company’s products include rituximab, an injection used to treat autoimmune diseases and cancers; bevacizumab, a medication targeting cancers and eye diseases. It also provides contract development and manufacturing services for the production of drug substances and products. mAbxience uses single-use bioreactor technology to manufacture its products in the therapeutic areas of oncology, osteoporosis, rheumatology, psoriasis and pediatrics. The company has research and development centers in Spain and Argentina. mAbxience is headquartered in Madrid, Spain.
For a complete picture of Etanercept biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
